This study is for women aged 18 and older with newly diagnosed Stage III or IV ovarian cancer, including certain types like high-grade serous. It's testing a treatment plan that starts with chemotherapy using carboplatin, paclitaxel, and pembrolizumab before surgery to remove the tumor. After surgery, you'll receive more chemotherapy, followed by maintenance treatment with olaparib and pembrolizumab. Researchers want to see if this treatment can help you live longer without the cancer growing or coming back (progression-free survival) over 36 months. The study is currently unclear on its recruitment status and plans to enroll about 20 participants.

Study design

This is a single-arm, Phase II study, meaning all participants receive the same treatment. It plans to enroll about 20 participants.

What's involved

You will receive chemotherapy before and after surgery, followed by maintenance chemotherapy. This includes a pre-treatment biopsy and another tissue sample during surgery.

Compensation

Not stated in the trial record.

Follow-up

Your progression-free survival will be measured at 36 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.